Relief Therapeutics shares collapse after COVID study shows no survival benefit
ZURICH, Feb 9 (Reuters) - Relief Therapeutics saidon Tuesday it had not determined if its experimental COVID-19treatment helped resolve respiratory failure and that there wasno survival benefit at 28 days, sending shares down as much astwo-thirds.
"The study has not yet determined results for the statedprimary endpoint of recovery from respiratory failure and thesecondary endpoint data reported today should not create anexpectation that the primary endpoint will be met overall or forany subgroup," Relief said in a release issued with its partner,NeuroRx.
"Differences in survival were not seen at day 28."
Patients who got Zyesami, the company's medicine, weredischarged from hospital care earlier than those got a placebo,the company said.
The shares, which had risen more than 1,000% in value sinceJuly, fell 65% at 1317 GMT to 0.18 Swiss francs.(Reporting by John Miller)
